Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
183.5(c) 185(c) 183.2(c) 178.9(c) 176.35 Last
475 668 462 244 375 179 752 369 683 625 Volume
+1.66% +0.82% -0.97% -2.35% -1.43% Change
More quotes
Estimated financial data (e)
Sales 2021 15 227 M 1 646 M 1 646 M
Net income 2021 2 424 M 262 M 262 M
Net Debt 2021 8 958 M 968 M 968 M
P/E ratio 2021 21,9x
Yield 2021 -
Sales 2022 16 154 M 1 746 M 1 746 M
Net income 2022 2 259 M 244 M 244 M
Net Debt 2022 5 617 M 607 M 607 M
P/E ratio 2022 23,5x
Yield 2022 -
Capitalization 52 049 M 5 604 M 5 626 M
EV / Sales 2021 4,01x
EV / Sales 2022 3,57x
Nbr of Employees 1 532
Free-Float 59,5%
More Financials
Company
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The CompanyÔÇÖs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the... 
Sector
Pharmaceuticals
Calendar
02/10 | 02:00amEarnings Release
More about the company
Ratings of Swedish Orphan Biovitrum AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
01/11Avalo Therapeutics Appoints Chief Commercial Officer
MT
2021Swedish Orphan Biovitrum Gets Positive Opinion From European Medicines Agency For COVID..
MT
2021Kineret« (anakinra) receives positive opinion from the CHMP for treatment of patients w..
AQ
2021Kineret« Receives Positive Opinion from the Committee for Medicinal Products for Human ..
CI
2021Swedish Orphan Biovitrum, Apellis Pharmaceuticals Win European Regulatory Nod For Blood..
MT
2021Apellis Pharmaceuticals Receives Approval From European Commission for Aspaveli
MT
2021Aspaveli« (pegcetacoplan) approved in EU as orphan drug for treatment of PNH
AQ
2021Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB Announce EU Approval of A..
CI
2021Swedish Orphan Biovitrum's Rare Blood Disease Therapy Achieves Haemoglobin Normalizatio..
MT
2021Apellis Pharmaceuticals Reports 46% Hemoglobin Normalization in Broad Paroxysmal Noctur..
MT
2021Aspaveli«/Empaveli™ (pegcetacoplan) demonstrated sustained normalisation of clini..
AQ
2021Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals, Inc. Announces New Data Demons..
CI
2021Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB Report Empaveli™áDem..
CI
2021Sobi continues the R&D transformationá-áAnders Ullman appointed new Head of R&D
AQ
2021Swedish Orphan Biovitrum AB Announces Executive Changes
CI
More news
News in other languages on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
01/24AVIS D'ANALYSTES DU JOUR : EDF, Arkema, Richemont, Zur Rose, Siemens, Swatch, Crédit Suiss..
01/14BOLSA DE MADRID : Good cop, bad cop
01/14Good cop, bad cop
01/14AVIS D'ANALYSTES DU JOUR : Safran, Novartis, Esker, Zalando, Shop Apotheke, Givaudan, Equi..
01/11Avalo Therapeutics nomme un responsable commercial en chef
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
More recommendations
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | SOBI | SE0000872095 | MarketScreener
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 178,90 SEK
Average target price 198,88 SEK
Spread / Average Target 11,2%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Hňkan Bj÷rklund Chairman
Anne Marie de Jonge Schuermans Head-Technical Operations & Senior Vice President
Sven Anders Ullman Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SWEDISH ORPHAN BIOVITRUM AB (PUBL)-3.35%5 676
CSL LIMITED-9.68%89 330
WUXI BIOLOGICS (CAYMAN) INC.-5.29%47 444
SAMSUNG BIOLOGICS CO.,LTD.-10.19%44 768
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.35%33 005